2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155460
    Pks13-TE inhibitor 4 3032947-26-2 98%
    Pks13-TE inhibitor 4 (compound 44) is an oxadiazole series Pks13 inhibitor that effectively inhibits tuberculosis (TB) and resolves its drug resistance.
    Pks13-TE inhibitor 4
  • HY-155461
    Antibiofilm agent-3 98%
    Antibiofilm agent-3 (compound 3b) is a tetracarboxamide antibacterial agent that effectively inhibits the plant bacterial pathogen Xanthomonas citri (Xanthomonas citri ssp. citri, Xcc) (MIC=500 μg/ mL). Antibiofilm agent-3 inhibits biofilm formation by Xcc with IC50=15.37 μg/mL.
    Antibiofilm agent-3
  • HY-155462
    hERG-IN-1 98%
    hERG-IN-1 (compound 2a) is an antibacterial agent and inhibitor of hERG. hERG-IN-1 inhibits pulmonary infection caused by Pseudomonas aeruginosa strain ATCC 27853.
    hERG-IN-1
  • HY-155479
    PqsR-IN-3 3033007-79-0 98%
    PqsR-IN-3 (compound 16e) is a selective inhibitor of the pqs system (IC50=3.7 μM) and its associated virulence factor pyocyanin (IC50=2.7 μM). PqsR-IN-3 inhibits bacterial biofilm synthesis and is significantly cytotoxic against Pseudomonas aeruginosa. PqsR-IN-3 has synergistic effects with several antibiotics, such as Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441).
    PqsR-IN-3
  • HY-155601
    SARS-CoV-2-IN-52 1001242-49-4 98%
    SARS-CoV-2-IN-52 (Compound 5) is an inhibitor for SARS-CoV-2 with a pIC50 of 0.3187.
    SARS-CoV-2-IN-52
  • HY-155862
    Antibacterial agent 152 197909-67-4 98%
    Antibacterial agent 152 (Compound 19) is an antibacterial agent. Antibacterial agent 152 displays moderate activity (MIC = 8-16 μg/mL) against Mycobacterium smegmatis MC2-155.
    Antibacterial agent 152
  • HY-15592R
    Cabotegravir (Standard) 1051375-10-0 98%
    Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS.
    Cabotegravir (Standard)
  • HY-155999
    MoTPS1-IN-1 2991072-02-5 99.50%
    MoTPS1-IN-1 (Compound j11), an antifungal agent, is a MoTPS1 inhibitor. MoTPS1-IN-1 acts by interation with Glu396 in MoTPS1. MoTPS1-IN-1 inhibits pathogenicity of M. oryzae.
    MoTPS1-IN-1
  • HY-156007
    SARS-CoV-2 3CLpro-IN-21 3052835-22-7 98%
    SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CLpro with an IC50 of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CLpro with an IC50 of 0.12μM.
    SARS-CoV-2 3CLpro-IN-21
  • HY-156021
    Antitubercular agent-40 900314-03-6 98%
    Antitubercular agent-40 (compound 93) is a thieno[2,3-b]quinoline-2-carboxamide compound with potential antitubercular activity.
    Antitubercular agent-40
  • HY-15602D
    Ledipasvir (diacetone) 1502655-48-2 98%
    Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
    Ledipasvir (diacetone)
  • HY-156052
    CN-716 dihydrochloride 2077164-48-6
    CN-716 dihydrochloride is a reversible covalent flavivirus NS2B·NS3 protease inhibitor with antiviral activity. CN-716 dihydrochloride effectively inhibits the replication of dengue virus (DENV2), West Nile virus (WNV) and Zika virus (ZIKV). The IC50 values of CN-716 dihydrochloride against the proteases of the above three viruses are 0.066 μM, 0.11 μM and 0.25 μM, respectively, while the Ki values against the same proteases are 0.051 μM, 0.082 μM and 0.04 μM, respectively. CN-716 dihydrochloride can be used to study the infection mechanisms of dengue fever, West Nile fever and Zika virus infection.
    CN-716 dihydrochloride
  • HY-156074
    Erythromycin propionate 134-36-1 98%
    Erythromycin propionate, erythromycin (HY-B0220) derivative, is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin propionate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin propionate toxicity is related to its inhibitory effect on bile acid transport.
    Erythromycin propionate
  • HY-156195
    BHBM 302807-84-7 98%
    BHBM (compound 1) is an aromatic acylhydrazone antifungal agent with high bactericidal activity against Cryptococcus neoformans.
    BHBM
  • HY-156198
    Bottromycin A2 15005-62-6 98%
    Bottromycin A2 is a natural antibiotic. Bottromycin A2 is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).
    Bottromycin A2
  • HY-156205
    CdnP-IN-1 691862-35-8 98%
    CdnP-IN-1 (compound c82) is a potent and selective non-nucleotide MTB CDN PDE (CdnP; Mycobacterium tuberculosis cyclic dinucleotide phosphodiesterase) inhibitor with an IC50 of 18 μM. CdnP-IN-1 does not inhibit the enzymatic activities of three other bacterial CDN PDEs (Yybt, RocR, and GBS-CdnP), a viral CDN PDE (poxin) or mammalian ENPP1.
    CdnP-IN-1
  • HY-156412
    DHFR-IN-10 929484-47-9 98%
    DHFR-IN-10 (compound 4c) is a potent DHFR inhibitor, with an IC50 of 4.21 μM for M. tuberculosis DHFR enzyme. DHFR-IN-10 exhibits potent antituberculosis efficiency.
    DHFR-IN-10
  • HY-156414
    DHFR-IN-11 98%
    DHFR-IN-11 (compound 6b) is inhibitor of DHFR, and has inhibitory potency versus M. tuberculosis DHFR enzyme with IC50 values 5.70 μM.
    DHFR-IN-11
  • HY-156416
    LtaS-IN-2 98%
    LtaS-IN-2 (compound 13) is a inhibitor of LTA synthesis, and shows antibacterial activity against S. aureus and S. epidermidis, with the MIC90 of 0.5 μg/mL and 1 μg/mL, respectively. LtaS-IN-2 is a derivative of LtaS-IN-1 (HY-135813).
    LtaS-IN-2
  • HY-156421
    QST4 2991427-35-9 99.23%
    QST4 has antitubercular activity, with the MIC value of 6.25 μM in Mycobacterium tuberculosis H37Rv.
    QST4
Cat. No. Product Name / Synonyms Application Reactivity